Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.
Indian Bank Q1 Result: PAT jumps 24% to Rs 2,973 crore on lower NPA provisions
Indian Bank reported a 24% YoY rise in Q1 net profit to Rs 2,973 crore, aided by sharply lower NPA provisions. Asset quality improved, with
July 24, 2025